Canada markets closed

Adaptive Biotechnologies Corporation (ADPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
36.61-0.59 (-1.59%)
At close: 4:00PM EDT
36.61 0.00 (0.00%)
After hours: 04:39PM EDT
Sign in to post a message.
  • k
    kastenz
    Norwegian vaccine company will use ADPT tech for 2021 trials, news pre-bell Jul-12.
  • C
    Chuck
    Up trade volume today, but the continuing slide down the rabbit hole. What will stop this misadventure?
  • k
    kastenz
    Lyme milestones ahead for 2021
  • C
    Chuck
    Insiders sold almost 100,000 shares in June @ $40 or less. If YOU thought the stock was going to mid 50's or 60 in a few months, would YOU sell? How many people on this board have bought shares this year? Insiders bought ZERO... Someone should tell these mental giants what SMART investors really do.
  • C
    Chuck
    Hmm, no insider selling so far this month.
  • k
    kastenz
    I've now listened to the Goldman Sac's interview with Adaptive's Chad Robbins half a dozen times. I guess the reason I find the talk so interesting is that it provides a complete explanation of how the company should be able to transform medicine all the way through infectious disease (including viral and Lyme), up through immune (Crohn's, celiac, colitis), and finally through cancer with accurate diagnosis, efficient therapies, including greatly reduced cost for the patient, clinics and payers. This is a little difficult to appreciate for two reasons, but it's finally starting to sink in.
  • k
    kastenz
    Good articles today on the virus variants and vaccines; ImmunoSEQ making it all a deterministic matter.
  • k
    kastenz
    I've reviewed trials at "ClinicalTrials.gov" with search term "ClonoSEQ". I reviewed half of the trials in the resulting list. Each one I reviewed specified the "Primary Outcome Measure: as "Molecular Residual Disease", direct quote, "Molecular residual disease (MRD) is defined as detection in blood samples by the ClonoSEQ test" I am satisfied ClonoSEQ is the gold standard for 'heme' cancers globally.
  • C
    Chuck
    Well, I guess somebody had to do it. Chad started the ball rolling by selling 20,000 shares for an easy $600,000, then Harlan jumped in with 11,600 for an easy $360,000 gain. Just had to do it, eh boys?
  • R
    RV
    ADPT needs to market T- Detect NOW!

    Best story about COVID 19 variants and Vaccine- written by a very good journalist in NY Times

    The studies may soothe fears that immunity to the virus is transient, as is the case with coronaviruses that cause common colds.
    CREDITCHRISTOPHER CAPOZZIELLO FOR THE NEW YORK TIMES
    Immunity to the Coronavirus May Persist for Years, Scientists Find
    Important immune cells survive in the bone marrow of people who were infected with the virus or were inoculated against it, new research suggests.

    15h ago
    By APOORVA MANDAVILLI

    But no mention of T detect! Why- because 99% of MDs and most of ID Specialists do not know or have heard about use of T cell epitopes. Time for ADPT to reach out with megaphones to educate them.
  • k
    kastenz
    Shares acting well, refusing to follow the market down this morning. Jun-10. I finished listening to the Jun-08 Goldman event. A lot of depth, at least for myself. I used their COVID T-detect test. The lack of liquidity in options (large bid/ask spreads) - can't figure this one out, why would that be?
  • R
    RV
    We need to use T detect before these papers on Neutralizing Antibodies (NAs) may tell us a different story- decreasing NAs are the story of life after vaccination or infection:

    Research looking at NAs:

    Medical Research Collaborative, LLC
    @MedResCol
    $AZN (and $JNJ ) jab likely to go out of use entirely in 2022. Also note waning NAbs w/ mRNA after just 4 months vs B.1.351:

    https://biorxiv.org/content/10.1101/2021.05.26.445838v1.full.pdf+html

    vs
    Research looking at specific T cell Epitopes

    Eric Topol
    @EricTopol
    Nearly all the work assessing vaccine protection vs variants has focused on neutralizing antibodies. A new study of T cells shows their intact response even to the most immune evasive variant, B.1.351
    https://immunology.sciencemag.org/content/6/59/eabj1750?utm_campaign=SciMag&utm_source=JHubbard&utm_medium=Twitter
    @SciImmunology
  • w
    widmeyer
    They had some interesting insights about ADPT on (http://Multistockalerts.com). Definitely made me think twice about the company.
  • k
    kastenz
    I added at 33. 50% rev growth 2021, partner roster impressive and growing, unique tech has major upside.
  • k
    kastenz
    Good demand for the shares, even though it's a few days since the webcasts, here on Jun-17.
  • R
    RV
    Nice to be in $40s again.
  • J
    JB
    ADPT is no start-up. It's had a name change and been out there floating around for for 5 years. Still, there are big names putting big money into this outfit. There will no doubt be many people holding their cards here because of that, after many have already folded.
  • C
    Chuck
    Chad just had to do it. Sold 20,000 shares at about 32. How many insiders have bought stock this year? Zero...
  • Y
    Yahoo Finance Insights
    Adaptive Biotechnologies is down 9.15% to 31.79
  • k
    kastenz
    BTIG cuts to 60 from 65, PT.